222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01185197 (ClinicalTrials.gov) | September 2010 | 13/8/2010 | Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study | Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome | Nephrosis, Lipoid | Drug: Myfortic plus low-dose steroid;Drug: Prednisolone | The University of Hong Kong | NULL | Completed | 18 Years | 65 Years | All | 20 | Phase 4 | China |